Format

Send to

Choose Destination
Gut Microbes. 2016 Sep 2;7(5):397-413. doi: 10.1080/19490976.2016.1215805. Epub 2016 Jul 26.

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.

Author information

1
a Department of Gastroenterology, Hepatology and Clinical Oncology , Medical Center for Postgraduate Education , Warsaw , Poland.
2
b Department of Genetics , Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Warsaw , Poland.
3
c Institute of Radioelectronics, Warsaw University of Technology , Warsaw , Poland.
4
d Department of Bioorganic Chemistry Wroclaw University of Technology , Wroclaw , Poland.
5
e Institute of Bioorganic Chemistry Polish Academy of Sciences , Poznań , Poland.

Abstract

Irritable bowel syndrome (IBS) is a chronic functional disorder and its development may be linked, directly and indirectly, to intestinal dysbiosis. Here we investigated the interactions between IBS symptoms and the gut microbiome, including the relation to rifaximin (1200 mg daily; 11.2 g per a treatment). We recruited 72 patients, including 31 with IBS-D (diarrhea), 11 with IBS-C (constipation), and 30 with IBS-M (mixed constipation and diarrhea) and 30 healthy controls (HCs). Of them, 68%, 64%, and 53% patients with IBS-D, IBS-C, and IBS-M, respectively, achieved 10-12 week-term improvement after the rifaximin treatment. Stool samples were collected before and after the treatment, and fecal microbiotic profiles were analyzed by deep sequencing of 16S rRNA, while stool metabolic profiles were studied by hydrogen 1-nuclear magnetic resonance ((1)H-NMR) and gas chromatography-mass spectrometry (GC-MS). Of 26 identified phyla, only Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria were consistently found in all samples. Bacteroidetes was predominant in fecal samples from HCs and IBS-D and IBS-M subjects, whereas Firmicutes was predominant in samples from IBS-C subjects. Species richness, but not community diversity, differentiated all IBS patients from HCs. Metabolic fingerprinting, using NMR spectra, distinguished HCs from all IBS patients. Thirteen metabolites identified by GC-MS differed HCs and IBS patients. However, neither metagenomics nor metabolomics analyses identified significant differences between patients with and without improvement after treatment.

KEYWORDS:

16s rRNA sequencing; irritable bowel syndrome; metabolomics; metagenomics; rifaximin

PMID:
27662586
PMCID:
PMC5046165
DOI:
10.1080/19490976.2016.1215805
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center